Outline the hybridoma method for the production of monoclonal antibodies

Question

Sourav · Answer

Here is a detailed outline of the Hybridoma Method for the production of Monoclonal Antibodies: I. Introduction to Hybridoma Technology

Definition: Hybridoma technology involves fusing short-lived antibody-producing B cells with immortal myeloma cells.
Purpose: To create cell lines that produce a continuous supply of a specific monoclonal antibody.
Creators: Developed in 1975 by Nobel prize-winning scientists Georges Kohler and Cesar Milstein.

II. Hybridoma Method Step-by-Step

Antigen Immunization
- Immunize an animal (typically a mouse) with a specific antigen.
B Cell Isolation
- Extract B cells from the immunized animal's spleen or lymph nodes.
Fusion with Myeloma Cells
- Fuse the B cells with immortal myeloma (cancer) cells.
- This creates hybrid cells, known as hybridomas.
HAT (Hypoxanthine-Aminopterin-Thymidine) Selection
- Select for hybridoma cells that have successfully fused.
- Unfused myeloma cells and B cells die off due to HAT.
Limiting Dilution Method
- Transfer hybridoma cells to ELISA plates at a concentration that allows for single-cell wells.
Screening for Antibody Production
- Identify wells with hybridoma cells producing the desired antibody.
- Test for specificity to the target antigen and epitope.
Cloning and Propagation
- Select and clone the desired hybridoma cells.
- Culture the cloned hybridoma cells in:
  - In Vitro systems (e.g., flasks, bioreactors) for high-purity antibodies.
  - In Vivo systems (e.g., injecting into mice) for larger quantities.

III. Key Outcomes and Advantages

Monoclonal Antibody Production: Unlimited supply of highly pure and specific antibodies.
Preservation of Native Antibody Structure: Maintains the natural pairing of constant and variable regions.
Versatility: Applicable across species, with potential for future advancements.

IV. Applications and Future Perspectives

Research: Identify surface proteins, define surface antigens, and localize molecules within cells or tissues.
Therapeutics: Production of sensitive and specific monoclonal antibodies for various diseases.
Continuous Improvement: Ongoing developments to enhance efficiency, screening, and validation processes.

Answer